Caregen Co., Ltd. (KOSDAQ:214370)

Market Cap	2.17T -15.7%
Revenue (ttm)	74.90B -7.6%
Net Income	22.87B -23.7%
EPS	468.29 -23.4%
Shares Out	48.87M
PE Ratio	95.03
Forward PE	n/a
Dividend	400.00 (0.91%)
Ex-Dividend Date	Jun 29, 2026

Volume	74,955
Open	44,250
Previous Close	43,850
Day's Range	43,250 - 45,250
52-Week Range	43,250 - 153,800
Beta	1.05
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 10, 2026

About Caregen

Caregen Co., Ltd., a biotechnology company, researches, develops, and commercializes biomimetic peptides worldwide. The company offers filler products under the REVOFIL, DR.CYJ, PROSTROLANE, PROSTROLANE B-Series, and CG Styler 600 names; skin care products under the Dermaheal, PURILUX whitening, Pim-Pim-Paul, and Neovert names; scalp care products under the Renokin and Pelo Baum names; and healthy foods under the proGsterol name. It is also developing medicines for COVID-19 treatment, wet macular degeneration, dry macular degeneration, antivira...

• Industry: Chemicals
• Sector: Materials
• Founded: 2001
• Employees: 193
• Stock Exchange: KOSDAQ
• Ticker Symbol: 214370

Financial Performance

In 2025, Caregen's revenue was 72.81 billion, a decrease of -11.84% compared to the previous year's 82.59 billion. Earnings were 20.10 billion, a decrease of -37.80%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 4, 2026

Data Sources Report a data error